^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fludarabine IV

    i
    Other names: NSC 312887, NSC-312887, NSC312887
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    1d
    Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies (clinicaltrials.gov)
    P1, N=48, Recruiting, Sawa Ito, MD | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • fludarabine IV • thiotepa • busulfan
    1d
    Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=33, Recruiting, City of Hope Medical Center | Trial completion date: Jun 2027 --> Nov 2028 | Trial primary completion date: Oct 2026 --> Nov 2028
    Trial completion date • Trial primary completion date • Platinum resistant
    |
    cyclophosphamide • fludarabine IV • TAG72-CAR T
    1d
    Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients (clinicaltrials.gov)
    P1/2, N=91, Recruiting, Curocell Inc. | Trial completion date: Feb 2028 --> Sep 2030 | Trial primary completion date: May 2023 --> Aug 2030
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • Rimqarto (anbalcabtagene autoleucel)
    1d
    A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov)
    P1/2, N=18, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1/2 trial
    |
    CD5 (CD5 Molecule)
    |
    fludarabine IV
    1d
    Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=51, Suspended, M.D. Anderson Cancer Center | Recruiting --> Suspended
    Trial suspension • Platinum resistant
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    cyclophosphamide • fludarabine IV • TROP2-CAR-NK
    2d
    Age-Stratified Conditioning Regimen Efficacy for MDS Haplo-HSCT (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Peking University People's Hospital
    New P2 trial
    |
    cytarabine • cyclophosphamide • fludarabine IV • busulfan
    2d
    Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Nathan Denlinger
    New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • Kymriah (tisagenlecleucel-T) • fludarabine IV
    2d
    ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (clinicaltrials.gov)
    P1, N=16, Completed, Acepodia Biotech, Inc. | Active, not recruiting --> Completed | N=42 --> 16 | Trial completion date: Sep 2027 --> Mar 2026 | Trial primary completion date: Jul 2026 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831
    3d
    RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, The Children's Hospital of Zhejiang University School of Medicine
    New P1 trial
    |
    cyclophosphamide • fludarabine IV
    3d
    IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=95, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial
    |
    EGFR expression
    |
    Erbitux (cetuximab) • cyclophosphamide • fludarabine IV
    5d
    Allogeneic hematopoietic stem cell transplantation for a pediatric case of myelodysplastic syndrome with germline DDX41 mutation. (PubMed, Ann Hematol)
    An 8-year-old female patient achieved bone marrow remission with azacitidine and venetoclax and subsequently underwent allogeneic hematopoietic stem cell transplantation from an unrelated umbilical cord blood donor, The conditioning regimen included fludarabine, decitabine, busulfan, and cyclophosphamide, leading to sustained donor engraftment. At the 13-month follow-up, the patient remained in complete hematologic remission without recurrence. This case suggests that allo-HSCT is a feasible curative option for children with high-risk MDS and germline DDX41 predisposition, highlighting the critical importance of screening potential donors for the same mutation.
    Journal
    |
    DDX41 (DEAD-Box Helicase 41)
    |
    Venclexta (venetoclax) • azacitidine • cyclophosphamide • decitabine • fludarabine IV • busulfan
    6d
    An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy (clinicaltrials.gov)
    P1, N=36, Recruiting, Changhai Hospital | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV • KN5501